{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cortellini A"],"funding":["National Institute for Health Research (NIHR)","Wellcome Trust"],"pagination":["9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8780322"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged overall (OS) and progression-free survival (PFS) following PD-1/PD-L1 checkpoint inhibitors. To validate our findings in patients with NSCLC, we evaluated two multicenter cohorts of patients with metastatic NSCLC receiving either first-line pembrolizumab or chemotherapy. From each cohort, 607 patients were randomly case-control matched accounting for FHC, age, performance status, and disease burden. Compared to FHC-low/negative, FHC-high patients experienced longer OS (HR 0.67 [95% CI 0.46-0.95], p = 0.0281), PFS (HR 0.65 [95% CI 0.48-0.89]; p = 0.0074) and higher disease control ra"],"journal":["Journal of hematology & oncology"],"pubmed_title":["High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status."],"pmcid":["PMC8780322"],"funding_grant_id":["PS3416"],"pubmed_authors":["Mazzoni F","Gelibter A","Addeo A","Santini D","Guida A","Giusti R","Rastelli F","Pecci F","Genova C","Buti S","Russo A","Filetti M","De Tursi M","Chiari R","Berardi R","Morabito A","Nigro O","Ricciardi S","Tuzi A","Mansueto G","Ghidini M","Bria E","Aerts JGJV","Della Gravara L","Macerelli M","Bertolini F","Grossi F","Zoratto F","Ficorella C","Friedlaender A","Gori S","Migliorino MR","Di Marino P","Metro G","Cortellini A","Marchetti P","Ferrara MG","Porzio G","Cantini L","Banna GL","Spinelli GP","Di Maio M","Antonuzzo L","Russano M","Tiseo M","Citarella F","Adamo V","Pinato DJ","Passiglia F"],"additional_accession":[]},"is_claimable":false,"name":"High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.","description":"Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged overall (OS) and progression-free survival (PFS) following PD-1/PD-L1 checkpoint inhibitors. To validate our findings in patients with NSCLC, we evaluated two multicenter cohorts of patients with metastatic NSCLC receiving either first-line pembrolizumab or chemotherapy. From each cohort, 607 patients were randomly case-control matched accounting for FHC, age, performance status, and disease burden. Compared to FHC-low/negative, FHC-high patients experienced longer OS (HR 0.67 [95% CI 0.46-0.95], p = 0.0281), PFS (HR 0.65 [95% CI 0.48-0.89]; p = 0.0074) and higher disease control ra","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-05-29T22:27:29.229Z","creation":"2025-05-29T22:27:29.229Z"},"accession":"S-EPMC8780322","cross_references":{"pubmed":["35062993"],"doi":["10.1186/s13045-022-01226-2"]}}